WE CLAIM:

1. An antibody that specifically binds to human FGFR-3, comprising a CDRH1 having the sequence GYMFTSYGIS (SEQ ID NO 1), a CDRH2 having the sequence WVSTYNGDTNYAQKFQG (SEQ ID NO 2), a CDRH3 having the sequence VLGYYDSIDGYYYGMDV (SEQ ID NO 3), a CDRL1 having the sequence GGNNIGDKSVH (SEQ ID NO 4), a CDRL2 having the sequence LDTERPS (SEQ ID NO 5), and a CDRL3 having the sequence QVWDSGSDHVV (SEQ ID NO 6), wherein human FGFR-3 is internalized and degraded upon binding to said antibody.
2. The antibody of claim 1, -wherein the antibody comprises a variable heavy amino acid sequence:
EVQLVQSGAEVKKPGASVKVSCKASGYMFTSYGISWVRQAPGQGLEWMGW
VSTYNGDTNYAQKFQGRVTVTTDTSTSTAYMELRSLRSEDTAVYYCARVLGYYDSI
DGYYYGMDVWGQGTTVTVSS (SEQ ID NO 7) and a variable light amino acid sequence:
QSVLTQPPSLSVAPGKTATFTCGGNNIGDKSVHWYRQKPGQAPVLVMYLDTERPSG
IPERMSGSNFGNTATLTITRVEAGDEADYYCQVWDSGSDHVVFGGGTKLTVLG
~~(SEQ ID NO 8)~~.
3. ~~The antibody of either of claims 1-2, comprising a heavy chain of SEQ ID NO: 9 and a light chain of SEQ ID NO: 10.~~
4. ~~An antibody as claimed in any preceding claim, comprising two heavy chains of SEQ ID NO: 9 and two light chains of SEQ ID NO: 10.~~

~~5.~~3. The antibody of any one of claims 1-~~2~~4 that specifically binds to mutant FGFR-3.

~~6.~~4. A pharmaceutical composition comprising an antibody or fragment, as claimed in any one of claims 1-~~3~~5 and a pharmaceutically acceptable carrier, diluent or excipient.

~~7.~~5. A product containing an antibody or fragment, according to any one of claims 1-~~3~~5, and an additional anti-cancer agent for treatment in combination for simultaneous, separate or sequential use in therapy.

~~8.~~6. An antibody or fragment as claimed in any one of claims 1-~~3~~5 for use as a medicament.

~~9.~~7. An antibody or fragment as claimed in any one of claims 1-~~3~~5, for use in the treatment of cancer.

~~10.~~8. A pharmaceutical composition comprising a compound according to any one of claims 1-~~3~~5 together with a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.

~~11. An antibody of any one of claims 1-5, wherein said antibody is conjugated with one or more other agents.~~

~~12. An antibody of any one of claims 1-5, wherein said one or more other agents is an anti-neoplastic agent.~~

~~13. An antibody of any one of claims 1-5, wherein said antibody is chemically or biosynthetically linked to an anti-tumor agent.~~

~~14. An antibody of any one of claims 1-5, wherein said antibody is chemically or biosynthetically linked to anti-tumor agents.~~

~~15. An antibody of any one of claims 1-5, wherein said antibody is chemically or biosynthetically linked to a detectable signal-producing agent.~~

~~16. An antibody of any one of claims 1-5, wherein said antibody is chemically or biosynthetically linked to detectable signal-producing agents.~~